General
Preferred name
ALBENDAZOLE
Synonyms
SKF-62979 ()
Albendazole (SKF-62979) ()
NSC-220008 ()
Zental ()
SK&F 62979 ()
Zentel ()
Albendazolum ()
Albenza ()
Andazol ()
Valbazen ()
SK&F-62979 ()
Eskazole ()
Albendazole-d7 ()
P&D ID
PD000815
CAS
54965-21-8
1287076-43-0
Tags
prodrug
natural product
drug
available
Approved by
FDA
First approval
1996
Drug Status
approved
vet_approved
Drug indication
Anthelmintic
Worm infection
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA Albendazole causes degenerative alterations in the tegument and intestinal cells of the worm by diminishing its energy production, ultimately leading to immobilization and death of the parasite. It works by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. As cytoplasmic microtubules are critical in promoting glucose uptake in larval and adult stages of the susceptible parasites, the glycogen stores of the parasites are depleted. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth.
Cell lines
1
Organisms
7
Compound Sets
24
AdooQ Bioactive Compound Library
A10049
Cayman Chemical Bioactives
23705
33542
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL1483
ChEMBL Drugs
CHEMBL1483
Drug Repurposing Hub
DrugBank
DB00518
DrugBank Approved Drugs
DB00518
DrugCentral
103
DrugCentral Approved Drugs
103
DrugMAP
DMYZ57N
DrugMAP Approved Drugs
DMYZ57N
DrugMatrix
Enamine BioReference Compounds
Ki Database
Albendazole
MedChem Express Bioactive Compound Library
HY-B0223
NCATS Inxight Approved Drugs
F4216019LN
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Albendazole(Albenza)
TargetMol Bioactive Compound Library
T1152
The Spectrum Collection
External IDs
49
Properties
(calculated by RDKit )
Molecular Weight
265.09
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
2
Aromatic Ring Count
2
cLogP
3.24
TPSA
67.01
Fraction CSP3
0.33
Chiral centers
0.0
Largest ring
6.0
QED
0.83
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
fungal tubulin polymerization inhibitor
tubulin polymerization inhibitor
Target
Tubulin
Microtubule
TUBA1A, TUBB, TUBB4B
antibiotic
Bacterial
HIF/HIF Prolyl-Hydroxylase
Microtubule/Tubulin
Parasite
Reactive Oxygen Species
VEGFR
ADC Cytotoxin,Microtubule Associated
Pathway
Cytoskeletal Signaling
Anti-infection
Apoptosis
Autophagy
Cell Cycle/DNA Damage
cytoskeleton
Immunology/Inflammation
Metabolic Enzyme/Protease
NF-κB
Protein Tyrosine Kinase/RTK
Indication
cystic hydatid disease, parenchymal neurocysticercosis
Therapeutic Class
Antiprotozoal Agents
Source data